GLAXO WELLCOME ONDANSETRON PANIC DISORDER NDA FILING PLANNED FOR FIRST HALF OF 1996; IMITREX SUPPOSITORY AND INTRANASAL NDAs ARE PENDING, COMPANY REPORTS
Executive Summary
Glaxo Wellcome is planning an NDA filing for ondansetron for treatment of panic disorder in the first half of 1996, R&D Group Medical Operations Director James Palmer told an R&D briefing for the financial community in New York City Nov. 10.